There are 412 resources available
Tissue and blood-based biomarkers of response to immunotherapy
Presenter: Marleen Kok
Session: Biomarkers-based treatment decision for early and metastatic breast cancer
Resources:
Slides
Webcast
181O - Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC)
Presenter: Peter Schmid
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Heterogeneity of treatment targets and markers of treatment resistance in metastatic breast cancer: Lessons learned from research autopsies
Presenter: Christine Desmedt
Session: Biomarkers-based treatment decision for early and metastatic breast cancer
Resources:
Slides
Webcast
Invited Discussant 179O, 180O and 181O
Presenter: Sara Tolaney
Session: Proffered Paper session 1
Resources:
Slides
Webcast
Systemic therapy horizons for hereditary breast cancer beyond BRCA
Presenter: Judith Balmana
Session: Actionability of germline variants beyond BRCA 1 and 2
Resources:
Slides
Webcast
Liquid biopsies: Current use, opportunities and challenges in metastatic breast cancer
Presenter: Nicholas Turner
Session: Biomarkers-based treatment decision for early and metastatic breast cancer
Resources:
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session 1
Resources:
Webcast
Q&A and discussion
Session: Actionability of germline variants beyond BRCA 1 and 2
Resources:
Webcast
Q&A and discussion
Session: Biomarkers-based treatment decision for early and metastatic breast cancer
Resources:
Webcast
Welcome and introduction
Presenter: Richard Finn
Session: Pfizer - Tailoring journeys: Customised care with CDK4/6 inhibitors in HR+ HER2- metastatic breast cancer
Resources:
Webcast